Serological profiles for HBV, HDV, HIV-1 and HTLV-1 in Saudi patients with a malignancy.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Serological profiles for HBV, HDV, HIV-1 and HTLV-1 in Saudi patients with a malignancy.

J Commun Dis. 1991 Dec;23(4):270-5. Unique Identifier : AIDSLINE MED/93107617
Arya SC; Ashraf SJ; Pathak VP; Nanda V; Parande CM; Tajuddin S; Centre for Logistical Research and Innovation, New Delhi, India.

Abstract: Serologic markers for HBV, HDV, HIV-1 and HTLV-1 were tested in 42 patients with a primary hepatocellular carcinoma (PHC); 19 with a malignancy of epithelial origin (EPM) and 16 with a non-epithelial malignancy (NEPM) in the Gizan Area of Saudi Arabia. HBV exposure in 77 PHC, EPM and NEPM patients was 92.2 per cent for any marker (overall) while 75.3 per cent positive for HBsAg. 3.9 per cent positive for anti-HBc and 12.9 per cent positive for anti-HBs. There was no inter PHC, EPM, NEPM or intersex variation for an individual marker or total HBV exposure. Among HBsAg-positives, 9 of the 12 PHC tested, 7 of the 10 EPM, 1 of the 9 NEPM were anti-D IgG positive. The HDV prevalence was the lowest in NEPM (p < 0.01). In patients with a malignancy, all HBV and HDV markers were higher than those of control population, even though anti-HBs was lower (p < 0.001). The probable contribution through different viruses in pathogenesis of malignancies of different types should be ascertained through polymerase chain reaction for viral components, oncogenes, etc. on tumourous biopsy tissues. The aggravation in PHC morbidity in HBV hyperendemic foci through HIV infection should be monitored through tests for unintegrated and integrated viral DNA in tumorous and non-tumorous tissues.

Keywords: Adolescence Adult Aged Aged, 80 and over Biological Markers/*BLOOD Carcinoma, Hepatocellular/*COMPLICATIONS Delta Infection/*BLOOD/EPIDEMIOLOGY/ETIOLOGY Female Hepatitis B/*BLOOD/EPIDEMIOLOGY/ETIOLOGY Human HIV Infections/*BLOOD/EPIDEMIOLOGY/ETIOLOGY *HIV-1 HTLV-I Infections/*BLOOD/EPIDEMIOLOGY/ETIOLOGY Liver Neoplasms/*COMPLICATIONS Male Middle Age Saudi Arabia/EPIDEMIOLOGY Seroepidemiologic Methods JOURNAL ARTICLE
930330
M9331084

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .